Tangier Disease Summary

304 relevant articles (7 outcomes, 21 trials/studies) found for this Disease

Description: An autosomal recessively inherited disorder caused by mutation of ATP-BINDING CASSETTE TRANSPORTERS involved in cellular cholesterol removal (reverse-cholesterol transport). It is characterized by near absence of ALPHA-LIPOPROTEINS (high-density lipoproteins) in blood. The massive tissue deposition of cholesterol esters results in HEPATOMEGALY; SPLENOMEGALY; RETINITIS PIGMENTOSA; large orange tonsils; and often sensory POLYNEUROPATHY. The disorder was first found among inhabitants of Tangier Island in the Chesapeake Bay, MD.

Also Known As: High-Density Lipoprotein Deficiency, Tangier Type; High-Density Lipoprotein Deficiency, Type I; Neuropathy of Tangier Disease; Tangier Hereditary Neuropathy; A alphalipoprotein Neuropathy Show All >>

Key Drugs and Agents for Tangier Disease

Efficacy Chart >>
Drugs and Important Biological Agents (IBA) related to treatments:

Apolipoprotein A-I (Apolipoprotein A1) : 2 outcomes 5 studies in 80 results : IBA
Apolipoproteins : 2 outcomes 2 studies in 42 results : IBA
Cholesterol : 1 outcome 7 studies in 100 results : IBA
Lipoproteins (Lipoprotein) : 1 outcome 6 studies in 103 results : IBA
Adenosine Triphosphate (ATP) : 1 outcome 3 studies in 56 results : IBA
Apoproteins : 1 outcome 2 studies in 6 results : IBA
Ca(2+) Mg(2+)-ATPase : 1 outcome in 1 result : IBA
Sterol O-Acyltransferase : 1 outcome in 1 result : IBA
Adenosine Triphosphatases (ATPase) : 1 outcome in 1 result : IBA
beta-lecithin : 1 outcome in 1 result : IBA

Show All >>

Diseases Related to Tangier Disease

Show All >>

Key Therapies for Tangier Disease

Efficacy Chart >>